Group 1 Automotive, Inc. filed an 8-K on September 24, 2026, disclosing that its subsidiary Group 1 Realty, Inc. entered into a master credit agreement with Bank of America, N.A. on September 23, 2026, providing for a term loan of up to $190,336,250.
Vertiv Holdings Co filed a Form 8-K on September 24, 2026, disclosing that one of its wholly-owned subsidiaries has entered into a definitive agreement to acquire King Environmental Services Ltd.
Starbucks Corporation filed an 8-K with the U.S. Securities and Exchange Commission on September 24, 2026, disclosing that its Board of Directors approved approximately 250 North America coffeehouse closures on September 22, 2026, under its "Back to Starbucks" strategy, with roughly $300 million in …
Darden Restaurants, Inc. filed a Form 8-K with the SEC on September 24, 2026, announcing that it had issued a news release reporting its fiscal 2027 first quarter results, declaring a quarterly dividend, and reaffirming its fiscal 2027 outlook.
TD SYNNEX Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission on September 24, 2026, disclosing financial results for its fiscal third quarter ended August 31, 2026, and announcing a quarterly dividend for the fourth quarter of fiscal year 2026.
Vistagen Therapeutics, Inc. filed a Form 8-K on September 24, 2026, reporting that the company issued a press release summarizing positive exploratory efficacy data for fasedienol nasal spray presented at Psych Congress 2026.
BlackBerry Limited filed a Form 8-K with the U.S. Securities and Exchange Commission on September 24, 2026, reporting that it issued a press release that same day announcing financial results for the fiscal quarter ended August 31, 2026.
Ligand Pharmaceuticals Incorporated filed a Form 8-K with the SEC on September 24, 2026, disclosing its entry into a financing agreement with AvenCell Therapeutics, Inc. for up to $47 million.
The Elmet Group Co. filed a Form 8-K on September 24, 2026, disclosing that on September 23, 2026, it entered into a Share Purchase Agreement and a Shareholders' Agreement to acquire a 4.99% interest in Masan High-Tech Materials Corporation for approximately $124,750,000.
Cullinan Therapeutics, Inc. filed a Form 8-K on September 24, 2026, disclosing anticipated immunology and oncology pipeline data readouts planned for the fourth quarter of 2026.